TARLATAMAB
UNII 74X82ST8Q1

Substance Identification & Data

This profile provides standardized clinical and technical data for Tarlatamab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 74X82ST8Q1.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2307488-83-9 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

74X82ST8Q1

CAS Registry Number

2307488-83-9

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TARLATAMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

74X82ST8Q1

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C175858

National Cancer Institute reference terminology for clinical and research data.

INN ID

11420

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

JK-173

Identifier assigned by the United States Adopted Names Council.

Substance Type

Tarlatamab

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tarlatamab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Tarlatamab

Tarlatamab-DLLE

Common Names & Synonyms

Immunoglobulin scFv-scFv-scFc, anti-[Homo sapiens DLL3 (delta-like ligand 3)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], monoclonal antibody single chain (scFv)2-scFc, bispecific; IG single chain scFv-scFv-scFc, antiDLL3 and anti-CD3E (1-982) [scFv-VH-V-kappa anti-DLL3 (1-241) [VH (Homo sapiens IGHV4-59*01 G49>C (44) (96.9%) -(IGHD) -IGHJ4*01 (100%)) CDRIMGT [8.7.12] (26-33.51-57.96-107) (1-118) -15-mer-tris(tetraglycyl-seryl) linker (119-133) -V-KAPPA (Homo sapiens IGKV3-20*01 (91.7%) -IGKJ2*01 Q120>C (234) (90.9%)) CDR-IMGT [7.3.9] (160-166.184-186.223-231) (134-241)] -6-mer-seryl-tetraglycyl-seryl linker (242-247) -scFv-VH-V-lambda antiCD3E (248-496) [VH (Mus musculus IGHV10-1*02 (91.9%) -(IGHD) -IGHJ3*01 (86.7%)/Homo sapiens IGHV3-73*01 (87.0%) -(IGHD) -IGHJ5*01 (100%)) CDR-IMGT [8.10.16] (273-280.298-307.346-361) (248-372)-15-mertris(tetraglycyl-seryl) linker (373-387) -V-LAMBDA (Homo sapiens IGLV7-43*01 (85.1%) -IGLJ3*02 (100%)) CDR-IMGT [9.3.9] (413-421.439-441.478-486) (388-496)] -4-mer-tetraglycyl linker (497-500) - scFc (h-CH2-CH3)-(hCH2-CH3) (501-982) [Homo sapiens IGHG1*03 h-CH2-CH3, nG1m1 (hinge 6-15 (501-510), CH2 R83>C (572), N84.4>G (577), V85>C (582) (511-620), CH3 E12 (636), M14 (638) (621-725), CHS>del) (501-725) -30-merhexakis(tetraglycyl-seryl) linker (726-755) -Homo sapiens IGHG1*03 h-CH2-CH3, nG1m1 (hinge 6-15 (756-765), CH2 R83>C (827), N84.4>G (832), V85>C (837) (766-875), CH3 E12 (891), M14 (893) (876-980), CHS (981-982)) (756-982)]], produced in Chinese hamster ovary (CHO) cells, nonglycosylated

Immunoglobulin, anti-(human notch ligand DLL3) (human monoclonal daeldhwzv-1 single-chain variable fragment VH1-(GGGGS)3-VL1) fusion protein with peptide linker (GGGGS) fusion protein with immunoglobulin anti-(human CD3 antigen ε-chain) (human monoclonal daeld-hwzv-1 single-chain variable fragment VH2-(GGGGS)3-VL2) fusion protein with peptide linker (GGGG) fusion protein with immunoglobulin G1 (human γ1-chain C-region C-terminal fragment) fusion protein with peptide linker (GGGGS)6 fusion protein with immunoglobulin G1 (human γ1-chain C-region C-terminal fragment)

TARLATAMAB [USAN]

Tarlatamab [MI]

Tarlatamab [WHO-DD]

Tarlatamab dlle [WHO-DD]

tarlatamab [INN]